Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2003 June;138(3) > Giornale Italiano di Dermatologia e Venereologia 2003 June;138(3):247-50

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

CLINICAL CASES   

Giornale Italiano di Dermatologia e Venereologia 2003 June;138(3):247-50

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: Italian

Imiquimod: a role as a topical therapy for epidermo-dysplasia verruciformis?

Gisondi P. 1, Giordano G. 2, Bignardi L. 3, Gasperini M. 1, Zendri E. 1, Bassissi P. 1, De Panfilis G. 1

1 Sezione di Dermatologia Dipartimento di Scienze Chirurgiche Università degli Studi di Parma, Parma 2 Sezione di Anatomia e Istologia Patologica Dipartimento di Medicina di Laboratorio Università degli Studi di Parma, Parma 3 Sezione di Nefrologia e Scienze della Prevenzione Dipartimento di Clinica Medica Università degli Studi di Parma, Parma


PDF


The aim of this study is the evaluation of efficacy of imiquimod, an immmune response modifier that enhances the cell-mediated cytolytic antiviral activity, for the topical therapy of epidermodysplasia verruciformis (EV), a HPV-related disorder. The drug had never been used before for the therapy of EV. A 52-year-old woman, affected by EV-like syndrome associated with renal transplantation, has been treated by imiquimod, on occlusive dressing, 3 times a week, for 3 months. At the end of treatment a discrete improvement of the lesions was observed. The conclusion is drawn that imiquimod, topically applied, induces a partial improvement of the lesions due to EV, even if its use has been officially recognized only for the treatment of anogenital condylomata.

top of page